NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne Medical Technologies (Nasdaq: NMTC) has received a notice of allowance from the USPTO for a key patent titled "Methods for Making Probe Devices and Related Devices." The patent application (17/392,773) covers novel methods for manufacturing neural probe devices, including specific processes for probe component arrangement and electrode contact material deposition.
The company's intellectual property portfolio now encompasses 17 issued and pending patents across the U.S. and internationally, covering various thin-film electrode technologies. The patent is expected to be formally issued in the coming months, strengthening NeuroOne's position in neural and spinal cord electrode technology.
NeuroOne Medical Technologies (Nasdaq: NMTC) ha ricevuto una comunicazione di concessione da parte dell'USPTO per un brevetto chiave intitolato "Metodi per la realizzazione di dispositivi probe e dispositivi correlati." La domanda di brevetto (17/392,773) riguarda metodi innovativi per la produzione di dispositivi probe neurali, inclusi processi specifici per la disposizione dei componenti della probe e per la deposizione del materiale di contatto degli elettrodi.
Il portafoglio di proprietà intellettuale dell'azienda comprende ora 17 brevetti concessi e in attesa negli Stati Uniti e a livello internazionale, che coprono diverse tecnologie di elettrodi a film sottile. Si prevede che il brevetto sarà formalmente rilasciato nei prossimi mesi, rafforzando la posizione di NeuroOne nella tecnologia degli elettrodi neurali e del midollo spinale.
NeuroOne Medical Technologies (Nasdaq: NMTC) ha recibido una notificación de concesión por parte de la USPTO para una patente clave titulada "Métodos para fabricar dispositivos de sonda y dispositivos relacionados." La solicitud de patente (17/392,773) abarca métodos novedosos para la fabricación de dispositivos de sondas neuronales, incluyendo procesos específicos para la disposición de componentes de la sonda y la deposición del material de contacto del electrodo.
El portafolio de propiedad intelectual de la empresa ahora incluye 17 patentes otorgadas y pendientes en Estados Unidos y a nivel internacional, que cubren diversas tecnologías de electrodos de película delgada. Se espera que la patente se emita formalmente en los próximos meses, fortaleciendo la posición de NeuroOne en la tecnología de electrodos neuronales y de la médula espinal.
NeuroOne Medical Technologies (나스닥: NMTC)가 "프로브 장치 및 관련 장치 제작 방법"이라는 핵심 특허에 대해 미국 특허청(USPTO)으로부터 허가 통지를 받았습니다. 특허 출원번호(17/392,773)는 신경 프로브 장치 제조를 위한 새로운 방법들을 포함하며, 프로브 구성 요소 배치 및 전극 접촉 재료 증착에 관한 구체적인 공정을 다룹니다.
회사의 지적 재산 포트폴리오는 현재 미국 및 국제적으로 다양한 박막 전극 기술을 포함하여 17건의 등록 및 출원 중인 특허를 보유하고 있습니다. 이 특허는 향후 몇 달 내에 공식적으로 발급될 예정이며, NeuroOne의 신경 및 척수 전극 기술 분야에서의 입지를 강화할 것입니다.
NeuroOne Medical Technologies (Nasdaq : NMTC) a reçu un avis d'acceptation de l'USPTO pour un brevet clé intitulé « Méthodes de fabrication de dispositifs de sonde et dispositifs connexes ». La demande de brevet (17/392,773) couvre des méthodes innovantes pour la fabrication de dispositifs de sonde neuronale, incluant des procédés spécifiques pour l'agencement des composants de la sonde et le dépôt du matériau de contact des électrodes.
Le portefeuille de propriété intellectuelle de la société comprend désormais 17 brevets délivrés et en cours aux États-Unis et à l'international, couvrant diverses technologies d'électrodes à film mince. Ce brevet devrait être officiellement délivré dans les prochains mois, renforçant la position de NeuroOne dans la technologie des électrodes neuronales et de la moelle épinière.
NeuroOne Medical Technologies (Nasdaq: NMTC) hat von der USPTO eine Zulassungsmitteilung für ein wichtiges Patent mit dem Titel „Methoden zur Herstellung von Sondengeräten und verwandten Geräten“ erhalten. Die Patentanmeldung (17/392,773) umfasst neuartige Methoden zur Herstellung neuronaler Sondengeräte, einschließlich spezifischer Verfahren zur Anordnung von Sondenkomponenten und zur Ablagerung von Elektrodenkontaktmaterial.
Das geistige Eigentumsportfolio des Unternehmens umfasst nun 17 erteilte und anhängige Patente in den USA und international, die verschiedene Dünnschicht-Elektrodentechnologien abdecken. Es wird erwartet, dass das Patent in den kommenden Monaten offiziell erteilt wird, was die Position von NeuroOne im Bereich neuronaler und spinaler Elektroden-Technologie stärkt.
- Receipt of USPTO notice of allowance for strategic patent application
- Robust IP portfolio with 17 issued and pending patents internationally
- Patent protection extends to both commercially available and developmental products
- None.
Insights
NeuroOne strengthens IP position with key neural probe patent allowance, protecting their core electrode technology across current and future products.
This patent allowance represents a significant strengthening of NeuroOne's intellectual property portfolio. The application titled "Methods for Making Probe Devices and Related Devices" covers novel manufacturing methods for neural probe devices, including specific electrode material deposition techniques that are central to the company's technology platform.
What makes this particularly valuable is that the patent appears to cover manufacturing methods applicable across NeuroOne's entire product line - both commercially available and in-development products. In the medical device industry, method patents can provide robust protection as they often cover specific technical approaches that competitors would need to use to achieve similar results.
The company's existing portfolio of 17 issued and pending patents demonstrates a strategic approach to IP protection, covering various aspects of their thin-film electrode technologies. This comprehensive coverage creates multiple layers of protection and potential barriers to competition.
A notice of allowance from the USPTO indicates that all examiner objections and rejections have been overcome, and the patent will be issued after payment of required fees. This final step before patent issuance significantly reduces uncertainty around this IP asset and validates the novelty and non-obviousness of NeuroOne's manufacturing approach for neural probe devices.
Patent Strengthens Intellectual Property Portfolio Surrounding Neural Probe Technologies
EDEN PRAIRIE, Minn., July 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office (USPTO) titled, “Methods for Making Probe Devices and Related Devices”. The U.S. Patent Application 17/392,773 is strategic in nature and covers novel methods of making neural probe devices, including specific steps for the arrangement of probe components and deposition of electrode contact material.
A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. NeuroOne anticipates the issuance of the patent in the coming months.
In addition to this allowed patent application, NeuroOne’s patent portfolio includes 17 issued and pending patents in the United States and internationally, covering a wide variety of thin-film electrode technologies. Among these include both neural and spinal cord electrodes with unique structures to optimize the functionality and minimize the profile of those electrodes.
“One of the key aspects with this patent relates to the novel method of electrode material deposition for all of our electrodes that are both commercially available and in development,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We believe that this new patent will better protect and advance our entire technology platform as we continue to develop and introduce new applications.”
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the anticipation of the issuance of the patent, and our business strategy, market size, and other potential growth opportunities. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
FAQ
What patent did NeuroOne (NMTC) receive approval for in July 2025?
How many patents does NeuroOne (NMTC) currently have in its portfolio?
What technologies are covered by NeuroOne's (NMTC) patent portfolio?
When will NeuroOne's (NMTC) new patent be officially issued?
